Contact Us / Sitemap / Directions / Patients and Visitors / Career Opportunities / Medical Staff
1-866-WINTHROP
pay your hospital bill pay your doctor's bill financial assistance policy
Winthrop University Hospital

BLOOD SAMPLES STUDY FOR STAGE III/ IV OVARIAN, PRIMARY PERITONEAL, OR FALLOPIAN TUBE CANCER

Summary

We are seeking volunteers to evaluate if a blood test, YKL-40, can help monitor your epithelial ovarian, primary peritoneal, or fallopian tube cancer prior to a physical exam or an imaging scan. We want to study the amount of YKL-40 in your blood before you start chemotherapy, during chemotherapy and after chemotherapy to see if the amount of YKL-40 goes down when the cancer treatment is working and the cancer cells are being killed. We also want to see if the amount of YKL-40 goes up if the cancer starts growing and spreading for any reason. Ideally, weÕd like to find more effective blood tests that can tell us what the cancer is doing before we can feel it during a physical exam or see it on a scan like a CTscan or MRI.

Description

Because you are participating in this study, you will need to provide about 2 teaspoons of blood at the following times for the YKL-40 test. The blood for the YKL-40 test will be obtained at the same time that blood is obtained for CA-125 test whenever possible. Before you begin chemo, prior to each cycle or initial chemo, and at 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42 and 48 months after finishing chemo. This is not a therapeutic protocol, treatment decisions for patients in the study will be made by the treating oncologist based on standard practice, using physical examination, CA125 results, and CT scan data.

Inclusion/exclusion

To be eligible for this study, patients must meet several criteria, including but not limited to the following: Any patients with Stage III or IV ovaruian, pertioneal, or fallopian cancer who had primary surgery Chemotherapy must start within 12 weeks of surgery Imaging (CTscan or MRI Scan) Prior to Study Entry and within 4 weeks of First Line Chemotherapy (to determine extent of disease) and at disease recurrence CA-125 and YLK-40 serum will be collected up to 18 time points

Principal Investigator

Jeannine Villella, D.O.

Department

Gynecology/Oncology

Email

jlbrown@winthrop.org

Other Contact

For more information, please contact Jennifer Brown, Research Cooridnator at 516-663-3115.
Contact Us / Sitemap / Directions / Career Opportunities / Financial Assistance / Policies
1-866-WINTHROP
subscribe
Winthrop-University Hospital
259 First Street | Mineola NY 11501 | 516-663-0333


This site provides information as a resource. It is not a substitute for professional medical advice.
Always consult a physician or healthcare provider for treatment and guidance toward good health.
Copyright © 2014 Winthrop-University Hospital. All rights reserved.
Web site by: Long Island Web Design
page-bottom